Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

Date publication

août 2015

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier , Dr SPAETH Dominique

Tous les auteurs :
Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset JL, Largillier R, Sautiere JL, de Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca FM,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26112003

Résumé

The 21-gene Oncotype DX Recurrence Score assay is a validated assay to help decide the appropriate treatment for estrogen receptor-positive (ER+), early-stage breast cancer (EBC) in the adjuvant setting. The choice of adjuvant treatments might vary considerably in different countries according to various treatment guidelines. This prospective multicenter study is the first to assess the impact of the Oncotype DX assay in the French clinical setting.

Mots clés

Adult, Aged, Biological Assay, methods, Breast Neoplasms, drug therapy, Chemotherapy, Adjuvant, methods, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Prospective Studies, Receptors, Estrogen, metabolism

Référence

Oncologist. 2015 Aug;20(8):873-9